Key facts
- Adults with type 2 diabetes on semaglutide 2 mg achieved similar HbA1c <7% as those on tirzepatide.
- Semaglutide 2 mg patients were more likely to achieve ≥5% weight loss than tirzepatide patients.
- Tirzepatide doses ranged from 2.5 mg up to 15 mg.
- The data is retrospective claims data.
Real-world data indicates that adults with type 2 diabetes who had their semaglutide dose increased from 1 mg to 2 mg demonstrated comparable effectiveness in achieving an HbA1c level below 7% when compared to patients switched to tirzepatide. Furthermore, the semaglutide group showed a higher likelihood of achieving a weight loss of 5% or greater. The tirzepatide group in this study received doses ranging from 2.5 mg, with the potential for titration up to 15 mg. This retrospective claims data analysis provides insights into the comparative outcomes of these two diabetes medications in a real-world setting.